CTOs on the Move

MiraVista Behavioral Health Center

www.miravistabhc.care

 
MiraVista is a new behavioral health treatment center opening April 2021 in the former Providence Hospital in Holyoke, MA. The newly renovated center will initially provide adult psychiatric and addiction treatment and will expand capacity to include child and adolescent services by the end of the year. Our mission is to provide compassionate, effective, sustainable care for those suffering from psychiatric distress and substance abuse. We are committed to helping fill the critical need for quality behavioral care in the Pioneer Valley and are excited to open our doors this Spring.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Lumeris

Lumeris is a value-based care managed services operator for health systems and providers seeking extraordinary clinical and financial outcomes. Lumeris aligns providers and payers across populations with technologies, processes, behaviors and information to achieve high-quality, cost-effective care with satisfied consumers — and engaged physicians. Lumeris with Essence Healthcare, its inaugural client with more than 60,000 Medicare members in Missouri and Illinois, has averaged a CMS rating of 4.5 Stars for the last ten years and produced the highest consumer and physician satisfaction scores in the industry along with significantly better clinical outcomes and lower costs.

Health One

Health One is a Ridgeland, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Piatt County Mental Health Center

Piatt County Mental Health Center is a Monticello, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PTPN

PTPN is a Calabasas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metamark

Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.